UNION therapeutics to present at the 7th Annual Evercore Healthcare Conference
Hellerup, Denmark, December 4, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CEO of UNION will present at the 7th Annual Evercore ISI HealthCONx Conference taking place on December 3-5, 2024 at The Loews Coral Gables Hotel in Coral Gables, Florida.
Dr. Kjøller will be presenting at 09:10am EST on Thursday, December 5, 2024, and will provide an update on orismilast and its potential across immunology as a safe oral treatment amidst injectable biologics. The presentation will include recent data from Phase 2 studies of orismilast in atopic dermatitis as well as hidradenitis suppurativa, demonstrating good effect on lesions as well as early symptomatic relief of core symptoms for patients. Orismilast has also generated positive results in psoriasis and is currently in development for ulcerative colitis, underscoring its potential as a safe oral treatment option across a broad range of immunological indications.
Contacts
Morten Boesen, Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
morten.boesen@uniontherapeutics.com
About UNION therapeutics
UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com
About orismilast
Orismilast is a next generation, high potency PDE4 inhibitor targeting the PDE4B/D subtypes linked to inflammation, demonstrating potent inhibition of Th1, Th2 and Th17 pathways. It acts early in the inflammation cascade, inducing a broad range of anti-inflammatory effects across multiple cytokines involved in many dermatological and immunological diseases.1) Orismilast is developed to have more potent anti-inflammatory properties than previously marketed PDE4 inhibitors, enabled by higher selectivity for subtypes PDE4B and D.
UNION is developing orismilast as an oral treatment, based on the well-known safety profile of the PDE4 class, across immunology, initially targeting best-in-class or first-in-class positions in atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis and ulcerative colitis (UC).
The FDA has cleared UNION’s Investigational New Drug (IND) application for oral orismilast and granted Fast Track designation for oral orismilast for the treatment of moderate to severe AD as well as for the treatment of moderate to severe HS.